Skip to main content
Clinical Trials/NCT03320447
NCT03320447
Completed
Phase 1

Long-term Efficacy of Ablative Fractional Laser-assisted Photodynamic Therapy for Treatment of Lower Extremity Bowen's Disease: A Prospective, Randomized, Controlled Trial With 5-year Follow up

Dong-A University0 sites60 target enrollmentStarted: October 30, 2011Last updated:

Overview

Phase
Phase 1
Status
Completed
Enrollment
60
Primary Endpoint
Difference of short-term complete response (CR) rate between AFL-PDT and MAL-PDT

Overview

Brief Summary

Er:YAG ablative fractional laser-assisted methyl aminolevulinate photodynamic therapy (AFL-PDT) has shown significantly higher efficacy and a lower recurrence rate at 12 months than methyl aminolevulinate photodynamic therapy (MAL-PDT) for treatment of Bowen's disease (BD). However, long-term follow up data are not available.

Detailed Description

To compare the long-term efficacy and recurrence rates of AFL-PDT and standard MAL-PDT for the treatment of lower extremity BD.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Factorial
Primary Purpose
Treatment
Masking
Triple (Participant, Investigator, Outcomes Assessor)

Eligibility Criteria

Ages
42 Years to 89 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • •Patients aged 18 years or more who diagnosed as bowen's disease

Exclusion Criteria

  • pregnancy or lactation
  • active systemic infectious disease
  • other inflammatory, infectious, or neoplastic skin diseases in the treated area
  • allergy to MAL,other topical photosensitizers, or excipients of the cream
  • history of photosensitivity
  • use of immunosuppressive or photosensitizing drugs
  • participation in any other investigational study in the preceding 30 days
  • history or indicators of poor compliance
  • Histological findings of acantholysis, desmoplasia, perineural or lymphovascular invasion, and echographic features of regional lymph node metastasis were the disease-specific exclusion criteria

Arms & Interventions

MAL-PDT

Experimental

Patients were randomly assigned to receive either AFL-PDT or MAL-PDT in a 1:1 ratio. As result, the patients were randomized to treatment with AFL-PDT or MAL-PDT

Intervention: methyl-aminolevulinate application (Drug)

MAL-PDT

Experimental

Patients were randomly assigned to receive either AFL-PDT or MAL-PDT in a 1:1 ratio. As result, the patients were randomized to treatment with AFL-PDT or MAL-PDT

Intervention: Illuminating using red light-emitting diode lamps (Device)

AFL-PDT

Experimental

Patients were randomly assigned to receive either AFL-PDT or MAL-PDT in a 1:1 ratio. As result, the patients were randomized to treatment with AFL-PDT or MAL-PDT

Intervention: lidocaine-prilocaine 5% cream application (Drug)

AFL-PDT

Experimental

Patients were randomly assigned to receive either AFL-PDT or MAL-PDT in a 1:1 ratio. As result, the patients were randomized to treatment with AFL-PDT or MAL-PDT

Intervention: methyl-aminolevulinate application (Drug)

AFL-PDT

Experimental

Patients were randomly assigned to receive either AFL-PDT or MAL-PDT in a 1:1 ratio. As result, the patients were randomized to treatment with AFL-PDT or MAL-PDT

Intervention: Illuminating using red light-emitting diode lamps (Device)

Outcomes

Primary Outcomes

Difference of short-term complete response (CR) rate between AFL-PDT and MAL-PDT

Time Frame: Short-term CR rate was evaluated at 3 months

The response was classified as either complete response (complete disappearance of the lesion) or incomplete response (incomplete disappearance of the lesion)

Difference of long-term complete response (CR) rate between AFL-PDT and MAL-PDT

Time Frame: Long-term CR rate was evaluated at 60 months

The response was classified as either complete response (complete disappearance of the lesion) or incomplete response (incomplete disappearance of the lesion)

Difference of long-term recurrence rate between AFL-PDT and MAL-PDT at 60 months

Time Frame: Recurrent rate was evaluated at 60 months

In all cases of complete response, the patients were reviewed at 60 months to check for recurrence. Post-therapy punch biopsies were performed when there was doubt concerning incomplete-response and clinical recurrence

Secondary Outcomes

  • Difference of the cosmetic outcome between AFL-PDT and MAL-PDT(Cosmetic outcome was assessed by each investigator for all lesions that achieved a complete response at 60 months)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Song Ki-Hoon

Associate professor

Dong-A University

Similar Trials